Filters

Search for: [Abstract = "Early abciximab administration before primary percutaneous coronary intervention \(PPCI\) for ST\-segment elevation myocardial infarction \(STEMI\) is believed to improve outcome. However, the evidence supporting abciximab use before and during transfer for PPCI is limited. Aim\: To assess safety and the effect of early abciximab administration in patients \(pts\) with first anterior wall STEMI. Methods\: A total of 59 non\-shock pts with STEMI <12h admitted to remote hospitals with anticipated delay to PPCI < 90 min were randomly assigned to two study groups – 27 pts received abciximab before transfer to cath lab \(early=group EA\) and 32 pts in cath lab immediately before PPCI \(late=group LA\). Results\: Better infarct\-related artery patency before PPCI and better ST\-segment resolution 60 min after PPCI was found in EA group. There was a significant difference in 30\-day left ventricular end\-systolic volume index\-ESVI and end\-diastolic volume index\-EDVI and a trend in ejection fraction\-EF in echocardiography favoring EA group. In cardiac magnetic resonance sub\-study lower ESVI, EDVI and higher EF was found in EA group after 1 year. A trend towards lower delayed enhancement infarct size was also observed in EA group. Similar rate of bleeding complications and major adverse events was found in both groups. Conclusions\: Early abciximab administration before transfer for PPCI in patients with first anterior wall STEMI is feasible and results in more frequent infarct\-related artery patency before PPCI, better myocardial tissue perfusion after PPCI and improved left ventricular function during 30\-day and 1\-year follow up."]

Number of results: 0

No results. Change search criteria.

This page uses 'cookies'. More information